Frontlight ResearchEarly access
Enrolling by invitationEarly phase 1
Imaging of Traumatic Brain Injury Metabolism Using Hyperpolarized Carbon-13 Pyruvate
Key facts
- Who runs it
- University of Texas Southwestern Medical Center
- Where
- Dallas, United StatesSee the site
- Trial code
- Status
- Enrolling by invitation
- Phase
- Early phase 1
- People taking part
- 60 people, planned
- Started
- 1 Jun 2018
- Expected to end
- 30 Dec 2026
- Type of study
- Interventional, 2 groups
- Treatments tested
- Hyperpolarized [1-13C] Pyruvate
- Hyperpolarized [2-13C] Pyruvate
- Record updated
- 3 September 2026
Who can take part
- Age
- 18 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 28 criteriaShow less
Who can take part
- TBI Patients
- Injury occurred within 30 days
- Documented and verified TBI by Glascow coma scal 10-15 and/or Loss of Consciousness >10 minutes
- Head Computed Tomography at admission; ALL Subjects:
- 18 through 60 years of age
- Ability to understand the the willingness to sign a writteninformed consent
- All races and ethnicities will be included; subjects must be able to read and speak either the English or Spanish language
Who cannot take part
- Under influence of illicit drugs which are known to alter brain physiology/metabolism including, but not limited to cocaine, lysergic acid diethylamide (LSD), and marijuana at the time of MRI/MRSI scanning
- Implants contraindicated at 3T, pacemakers
- Subjects who are receiving any other investigational agents
- Significant anatomic distortion of the brain identified on CT images, such as large hematomas, herniation, intraventricular hemorrhage, extensive subarachnoid hemorrhage, hydrocephalus
- Patients on psychiatric hold
- Major debilitating mental health disorders including, but not limited to schizophrenia and bipolar disorder that would limit compliance with study requirements
- Major debilitating neurological disease including, but not limited to, stroke, CVA, dementia and tumor that would limit compliance with study requirements
- Heart failure
- Unstable angina
- Non-traumatic structural brain abnormality identified on head CT
- Metallic foreign bodies on the scalp or cranium which may interfere with MRI acquisitions
- Penetrating TBI
- Significant polytrauma that would interfere with follow-up and outcome assessment
- Any contraindication per MRI Screening Form including
- Implantable Cardioverter Defibrillator (ICD)
- Claustrophobia
- Prisoners or patients in custody
- Medically unstable including
- Severe left ventricular outflow tract (LVOT) obstruction
- Pregnancy
- Lactating
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Where in United States
- UT Southwestern - Advanced Imaging Research CenterDallas, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
This project is to evaluate sensitivity and specificity of hyperpolarized 13C-pyruvate as imaging agents of altered cerebral glycolysis and mitochondrial dysfunction and assess pyruvate utilization in mitochondria in Traumatic Brain Injury (TBI) patients.
The 2 groups in the trial
- Hyperpolarized [1-13C] PyruvateTreatment being tested
Injection with hyperpolarized \[1-13C\] Pyruvate during MRI.
- Hyperpolarized [2-13C] PyruvateTreatment being tested
Injection with hyperpolarized \[2-13C\] Pyruvate during MRI.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT03502967, who can take part
- Record updated
- 3 September 2026